Is Insulet Corporation (PODD) overvalued? · P/E 34, rev $2.07B
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
This page asks whether Insulet Corporation (PODD) looks expensive on cached numbers — not a short thesis.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
PODD currently screens at market cap $9.94B and trailing P/E 33.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PODD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PODD stock page for the full model, not this heading.
Not investment advice.